

Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis

Monica Marta^{1,2}, David Baker¹, Paul Creeke¹, Gareth Pryce¹, Sharmilee Gnanapavan^{1,2}, Gavin Giovannoni^{1,2}

¹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom,

²Clinical Board:Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom

Correspondence: Gavin Giovannoni/Monica Marta, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, E1 2AT, United Kingdom. Email. g.giovannoni@qmul.ac.uk/m.calado-marta@qmul.ac.uk. Tel +44 207882 8954.

Keywords: beta interferon, clinical trial, immune tolerance, mitoxantrone, multiple sclerosis,

Email:

Monica Marta	m.calado-marta@qmul.ac.uk
David Baker	david.baker@qmul.ac.uk
Gareth Pryce	gpryce58@gmail.com
Paul Creeke	paul.creeke@gmail.com
Sharmilee Gnanapavan	s.gnanapavan@qmul.ac.uk
Gavin Giovannoni	g.giovannoni@qmul.ac.uk

ABSTRACT

Background: Antigen-specific tolerance in auto-immune diseases is the goal for effective treatment with minimal side-effects. Whilst this is achievable in animal models, notably via intravenous delivery of the model-specific autoantigen following transient CD4 T cell depletion, specific multiple sclerosis autoantigens remain unproven. However, anti-drug antibodies to human therapeutic proteins represent a model human autoimmune condition, which may be used to examine immune-tolerance induction. Some people with MS (PwMS) on interferon-beta1a (IFN β 1a) develop neutralizing antibodies to IFN β 1a that do not disappear in repeated tests over years.

Methods: One PwMS was recruited, as part of a planned phase IIa trial (n=15), who had developed neutralizing antibodies to subcutaneous IFN β 1a. Mitoxantrone (12mg/m 2) was administered as a lymphocyte depleting agent followed by four days of (88 μ g/day + three 132 μ g/day) intravenous IFN β 1a. Subcutaneous IFN β 1a three times a week was maintained during follow-up. IFN β 1a neutralizing antibody responses in serum were measured during treatment and three-monthly for 12 months.

Findings: One participant was recruited and, within 6 months of tolerization, the neutralizing antibodies were undetectable. The tolerization treatment was well tolerated. However, the study was terminated after the first enrolment, on ethical grounds, as treatment alternatives became available and the potential risks of mitoxantrone use increased.

Interpretation: The data suggest that it may be possible to induce antigen-specific tolerance by providing tolerogenic antigen following transient immune depletion. Further studies are warranted.

Funding: The study was supported by an unrestricted research grant from Merck-Serono.

INTRODUCTION

Multiple sclerosis (MS) is an immune-mediated, demyelinating disease of the central nervous system. Although inhibition of relapsing inflammatory disease is possible, such immunotherapy can be associated with side-effects following the non-selective targeting of large parts of the immune system (Marta & Giovannoni 2012). Antigen-specific therapy would offer the benefit to selectively target pathogenic cells and is already and consistently achievable in experimental (auto)immunity via delivery of autoantigens via tolerogenic, notably intravenous, routes following transient T-cell depletion (Polak & Turk 1969; Lanoue et al. 1997, Pryce et al. 2005; Smith et al. 2005). The challenge is to translate this simple combinational approach into human autoimmunity in general and into MS in particular. Although T-cell depleting antibodies succeeded in experimental animals (Polak & Turk 1969; Lanoue et al. 1997; Pryce et al. 2005), the failure of CD4-antibody-mediated depletion in MS (van Oosten et al. 1997) meant that alternative depleting drugs would be required for clinical studies. Mitoxantrone is an immunosuppressive agent that had a role for the treatment of aggressive MS and could be used as a depleting drug to promote tolerance induction (Pryce et al. 2005; Cocco & Marrosu 2014; Martinelli Boneschi et al. 2013). However, the autoantigens in MS are unknown and attempts to induce antigen-specific tolerance via monotherapy have, unsurprisingly, consistently failed (Weiner et al. 1993; Kappos et al. 2000; Garren et al. 2008; Freedman et al. 2011; Lutterotti et al. 2013; van Noort et al. 2015; Lutterotti et al. 2019). Nevertheless, there are autoimmune conditions where the autoantigen is known, and one example is the anti-drug antibody response to a therapeutic human protein. Some people treated with human interferon beta1a (IFN β 1a) develop neutralizing antibody responses that can stop IFN β 1a working (Vallbracht et al 1981; Abdul-Ahad et al. 1997; Farrell et al. 2011). In other autoimmune disorders such as rheumatoid arthritis, Sjögren's and Crohn's disease, concomitant methotrexate use attenuates neutralizing antibody frequency, but not all disease-modifying agents have been demonstrated to impact on immunogenicity (Jani et al. 2014). Although there are currently many treatment options for relapsing MS, when this study started, only IFN β 1 and glatiramer acetate were available in the United Kingdom (Marta & Giovannoni 2012). The development of neutralizing antibodies could mean treatment failure (Farrell et al. 2011). This study was designed to test the hypothesis that a combination of lymphocyte depletion with mitoxantrone and intravenous IFN β 1a could reverse IFN β 1a-specific neutralizing antibody response.

METHODS

Study Design: The single-centre, open-label phase IIa study was conducted in accordance with the Declaration of Helsinki/International Conference on Harmonisation-Good clinical practice was approved by the Cambridgeshire 4 Research Ethics Committee (REC 08/H0305/64) in 2009. There was no adequate data for sample size calculation. The study planned to recruit n=15 people.

Registration: EudraCT number 2008-000256-26

Inclusion criteria: People with clinically-definite MS (according to McDonald 2005 criteria) MS (PwMS), aged 18-65 years and with Expanded Disability Status Scale ≤ 6.5 , who had received IFN β 1a (subcutaneous Rebif®-22/44 three times a week or weekly intramuscular Avonex®) for at least 12 months. If they had at least one significant relapse in the prior 12 months and were considering switching therapy, consent was sought. Participants with two consecutive positive neutralizing antibody tests (titre >20U), at least 4 weeks apart, could participate. Male or female participants had to agree to adequate contraception during the study and females had to have a negative pregnancy test at screening.

Exclusion criteria: People treated with immunosuppressive, immunomodulatory or experimental treatments within the 6 months prior to enrolment, except for steroid use for treatment of relapse or IFN β 1a, were excluded. In addition, participants should not exhibit a history of liver toxicity or abnormal liver function tests (>2.5 times upper limit of normal); poorly controlled diabetes; hypertension; severe cardiac insufficiency, unstable ischaemic heart disease, left ventricular ejection fraction <50% on echocardiogram or an abnormal 12-lead electrocardiogram; complete white blood cell counts <1.5 the lower limit of normal; or have any medical condition which, in the opinion of the chief investigator, would pose additional risk. Participants could not have chronic or recurrent infections or human immunodeficiency virus, a history of malignancy or drug or alcohol abuse and should not be pregnant or breastfeeding.

Treatment Intervention: Single 12mg/m² intravenous mitoxantrone infusion (Day 0). On day 14, two 44 μ g intravenous IFN β 1a (Rebif® new formulation) injections (88 μ g/day), if the first 44 μ g dose was tolerated. This was followed by four daily intravenous injections of 132 μ g/day (total dose 660 μ g). If safe in the initial five participants, the dose would be escalated to a total dose of 1320 μ g in a second cohort (264 μ g/day. n=5) and a third cohort (n=5) of 2640 μ g over 5 days. The maximum dose administered was calculated to limit excessive exposure of bioactive intravenous IFN β 1a after saturation (quenching) of neutralizing antibodies. Participants would stay on their IFN β 1a treatment for the rest of the year-long study.


Outcome measures: The primary outcome was to assess the therapeutic safety and efficacy of intravenous IFN β 1a after transient peripheral leucocyte depletion. Planned secondary outcomes were to measure T-cell proliferation to IFN β 1a, and T and B cell cytokine responses relative to baseline, compared to response to tetanus toxoid control antigen. Tertiary outcomes were to measure neutralizing antibody titre at 3, 6, 9 and 12 months relative to baseline. Serum neutralizing antibody responses were monitored using a validated luciferase-based reporter neutralizing assay (Lam et al. 2008; Farrell et al. 2011).

Safety: Adverse events were monitored throughout the trial. Laboratory (Haematology and biochemistry) tests and physical examinations were performed at screening, during drug treatment days and 3-monthly trial visits.

RESULTS

The trial was planned in 2006 and funding obtained in 2007. Regulatory approval was sought in early 2008 and was granted in early 2009. However, recruitment was delayed whilst accredited neutralizing antibody assays were brought in-house. Recruitment for the trial was slow and only one participant was enrolled by the end of 2012 (Figure 1). The trial was terminated in 2013 due to ethical concerns related to the higher than predicted risk posed by the use of mitoxantrone in MS (Ellis et al. 2013) and other licenced and effective alternatives becoming available. The participant received only four (88 μ g/day and three 132 μ g/day) cycles of intravenous IFN β 1a, as they developed grade 4 neutropenia (which subsequently resolved) so the last daily dose was not injected, as per protocol. There were no other relevant serious adverse events. There were 8 adverse events recorded (Supplementary data. Figure 1S). With only one participant, we did not evaluate secondary (immune parameters) outcomes. In the trial participant, the neutralizing antibody levels dropped below the level of detection within 3 months and in following serum samples (Figure 1). Serial analyses of serum samples from 13 people with MS treated with IFN β 1a three times a week over a period of 1 year failed to show any case of reduced neutralizing titres (Figure 1). This supports the view that antigen-specific immune tolerance to IFN β 1a may have been induced.

Figure 1. *Intravenous IFN β 1a-specific tolerance induction inhibited neutralizing antibody responses.*



Individual IFN β 1a neutralizing antibody (Nab) responses at baseline and 1 year later in people treated with 44 μ g IFN β 1a subcutaneously three times a week ($n=13$) and the response in the trial participant receiving an infusion of mitoxantrone (Mitox) followed four days of intravenous IFN β 1a.

DISCUSSION

This case-study suggests that it may be possible to induce antigen-specific tolerance to proteins in humans. The combination of lymphocyte depletion with mitoxantrone followed by intravenous high-dose antigen, eliminated autoimmune antibody responses and thus contrasts with the lack of efficacy following high-dose intravenous IFN β 1 monotherapy (Hegen et al. 2014). Whilst our study lacked supportive mechanistic *in vitro* data, due to early trial termination, varied mechanisms of intravenous tolerance have been well studied in animals and humans (Smith et al. 2005; Lutterotti et al. 2013). Although intravenous tolerance develops within hours (Pryce et al. 2005), immunoglobulin half-life is about 3-4 weeks (Waldmann & Strober 1969), which is consistent with the decrease in titre of neutralizing antibodies over months. Although promising, the trial was terminated early. This was because an oral, higher efficacy, alternative drug became available that could be used following treatment failure with IFN β 1 (Polman et al. 2006; Weissert 2006). Notably fingolimod was approved for use in the United Kingdom in 2013 and was more attractive than continuing on frequent lower-efficacy, injectable therapies. Natalizumab was approved for use in the United Kingdom National Health Service but not widely available as the use was restricted to rapidly evolving, severe, relapsing MS. In addition, prior mitoxantrone use increased the risk for progressive multifocal leukoencephalopathy during natalizumab treatment (Faulker 2015). During this period, mitoxantrone was also reported to cause worse fertility complications (Cocco et al. 2008) and importantly, studies emerged showing that the risk of mitoxantrone-induced leukaemia had doubled (Ellis & Boggild 2009; Ellis et al. 2015). Therefore, even if we hypothesized that treatment could reduce infection risks associated with inhibition of endogenous IFN intrinsic pathways (Fine et al 2014), it was not ethically justifiable to expose people to the procedure and thus the planned trial became an anecdotal case report.

It is possible that loss of the neutralization response was unrelated to treatment, but this would be unlikely, as it was not found in non-tolerized individuals and those given intravenous IFN β 1a alone (Hegen et al. 2014). Monotherapy, intravenous tolerance continues to be trialled and repeatedly found to be insufficiently successful in MS (Freedman et al. 2011; Hegen et al. 2014; Lutterotti et al. 2013; van Noort et al. 2015), as would be predicted from extensive animal studies, even if the correct autoantigens were selected (Lanoue et al. 1997; Pryce et al. 2005). These studies indicate the essential need to deplete pathogenic cell subsets prior to tolerance induction in established disease and thus casts doubt on the value of tolerogenic monotherapy without prophylactic lymphocyte depletion (Lanoue et al. 1997; Pryce et al. 2005; von Kutzleben et al. 2017; Krienke et al. 2021). Although neutralizing responses to other therapeutic proteins can be a problem in MS (Dubuisson et al. 2018; Baker et al. 2020), given the variety of current treatments (Dobson and Giovannoni 2019), MS is perhaps not the best disease to develop this approach further. However, targeting neutralizing responses to antibodies that provide life-saving function

(Patriquin & Kuo 2019) or autoimmune disease with a defined autoantigen and limited treatment options may be a better target for future studies.

ACKNOWLEDGEMENTS. The authors would like to thank Forian Deisenhammer and Mike Boggild and for providing advice on the intravenous delivery of IFN β 1a and mitoxantrone risk assessment.

FUNDING. The study was supported by an unrestricted research grant from Merck-Serono.

DECLARATION OF INTERESTS. The authors declare that the research was conducted in the absence of any commercial or financial relationships. At the time DB had nothing to declare. However, DB has received consultancy and presentation fees from Canbex Therapeutics, InMune Bio, Lundbeck, Novartis, Merck and Roche. MM has received honoraria or meeting support from Novartis, Roche and Sanofi-Genzyme. GG has received consultancy, presentation fees or grants from Abbvie Biotherapeutics, Actelion, Atara Bio, Biogen, Canbex, Celgene, Genentech, Japan Tobacco, Merck, Novartis, Roche, Sanofi-Genzyme, Synthon, Takeda, and Teva. SG has received travel support, consultancy fees or grant support from Biogen, Novartis, Teva, Pfizer, and Takeda.

AUTHOR CONTRIBUTION. Concept: DB, GP, MM, GG, Initial Draft: DB, MM; Assays: PC; Study recruitment: MM, SG, GG; Study funding: GG; Regulatory Issues: GG, SG, MM; Trial conduct MM, GG; Final manuscript: All

DATA SHARING STATEMENT: Anonymous data is available on request

REFERENCES

Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. *Cytokines Cell Mol Ther.* 1997; 3:27-32.

Baker D, Ali L, Saxena G, Pryce G, Jones M, Schmierer K, Giovannoni G, Gnanapavan S, Munger KC, Samkoff L, Goodman A, Kang AS. The irony of humanization: Alemtuzumab the first, but one of the most immunogenic, humanized monoclonal antibodies. *Front Immunol* 2020. Provisionally accepted.

Cocco E, Sardu C, Gallo P, Capra R, Amato MP, Trojano M, Uccelli A, Marrosu MG; FEMIMS Group. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. *Mult Scler*; 14:1225-1233.

Dobson R, Giovannoni G. Multiple sclerosis - a review. *Eur J Neurol.* 2019;26(1):27-40.

Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S, Giovannoni G, Schmierer K. Alemtuzumab depletion failure can occur in multiple sclerosis. *Immunology.* 2018; 154:253-260.

Ellis R, Boggild M. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? *Mult Scler.* 2009; 15:505-508.

Ellis R, Brown S, Boggild M. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited? *Mult Scler.* 2015; 21:642-645.

Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G. Incorporation of an interferon- β neutralizing antibody assay into routine clinical practice. *Mult Scler.* 2011; 17:1333-1340.

Faulkner M. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. *Expert Opin Drug Saf.* 2015; 14:1737-1748.

Fine D, Dattani A, Moreira I, Giovannoni G, Marta M. Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways? *Mult Scler Relat Disord.* 2015; 4:88-91.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators. A phase III study evaluating the

efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011; 77:1551-1560.

Hegen H, Guger M, Harrer A, Hoelzl M, Kraus J, Skrobal A, Schautzer F, Schmidegg S, Schocke M, Deisenhammer F. High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study. Mult Scler Relat Disord. 2014; 3:220-226

Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L; BHT-3009 Study Group. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol. 2008; 63:611-620.

Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatol 2014; 53: 213-222.

Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, Akilli-Ozturk Ö, Kranz LM, Berger H, Petschenka J, Diken M, Kreiter S, Yoge N, Waismann A, Karikó K, Türeci Ö, Sahin U. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021; 371:145-153.

Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods. 2008; 336:113-118.

Lanoue A, Bona C, von Boehmer H, Sarukhan A. Conditions that induce tolerance in mature CD4+ T cells. J Exp Med. 1997;185:405-414.

Lutterotti A, Yousef S, Sputtek A, Stürner KH, Stellmann JP, Breiden P, Reinhardt S, Schulze C, Bester M, Heesen C, Schippling S, Miller SD, Sospedra M, Martin R. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med. 2013;5(188):188ra75.

Lutterotti A, Ludersdorfer TH, Docampo MJ, Hohmann M, Selles Moreno C, Hayward-Koennecke H, Pfender N, Jelic I, Meuller T, Blumer C, Schippling S, Foege S, Winklhofer S, Stenger R, Kayser M, Schanz U, Sospedra M, Martin M. Establish tolerance in MS with myelin-peptide coupled red blood cells-the Phase Ib ETIMSredtrial. 339. Mult Scler 2019;25(S2) 894.

Marta M, Giovannoni G. Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon. CNS Neurol Disord Drug Targets. 2012; 11:610-623.

- Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. *Cochrane Database Syst Rev*. 2013; (5):CD002127.
- Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. *Nat Med*. 2000; 6:1176-1182.
- Patriquin CJ, Kuo KHM. Eculizumab and Beyond: The past, present, and future of complement therapeutics. *Transfus Med Rev*. 2019 Oct 22. pii: S0887-7963(19)30132-4.
- Polák L, Turk JL. Studies on the effect of systemic administration of sensitizers in guinea-pigs with contact sensitivity to inorganic metal compounds. 3. The effect of immunosuppressive agents on enhancing the unresponsiveness of already sensitized animals and an investigation of the action of the epicutaneous test within twenty-four hours. *Clin Exp Immunol*. 1969; 4:423-434.
- Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*. 2006; 354:899-910.
- Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D. Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. *J Neuroimmunol*. 2005; 165:41-52.
- Smith PA, Morris-Downes M, Heijmans N, Pryce G, Arter E, O'Neill JK, 't Hart B, Baker D, Amor S. Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice. *J Neuroimmunol*. 2005; 164:76-84.
- Vallbracht A, Treuner J, Flehming B, Joester KE, Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. *Nature*. 1981; 289:496-497.
- van Noort JM, Bsibsi M, Nacken PJ, Verbeek R, Venneker EH. Therapeutic intervention in multiple sclerosis with alpha B-crystallin: A randomized controlled phase IIa trial. *PLoS One*. 2015; 10:e0143366.
- van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Rudge P, McDougall A, McLeod JG, Adèr HJ, Polman CH. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cm-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. *Neurology*. 1997; 49:351-357.

von Kutzleben S, Pryce G, Giovannoni G, Baker D. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. *Immunology*. 2017; 150:444-455.

Waldmann TA, Strober W. Metabolism of immunoglobulins. *Prog Allergy*. 1969; 13:1-110.

Weiner HL, Mackin GA, Matsui M, Orav EJ, Khouri SJ, Dawson DM, Hafler DA. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. *Science*. 1993; 259:1321-1324.

Weissert R. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived. *Expert Rev Neurother*. 2006; 6:1587-1590.

Supplementary Data

Figure 1S. Adverse events by Body system for the duration of the trial

Body System	Number of Reports
Endocrine Total: Neutropenia Lymphopenia	2 1 1
Cardiovascular Total: Hypotension	1 1
Lymph Nodes Total:	0
Skin Total: Alopecia Cold Sore	2 1 1
Musculoskeletal Total: Back pain	1 1
Neurologic Total: Numbness of fingers	1 1
Other Total: Rigors	1 1
TOTAL for all systems	8